Sponsor |
Study Name and Link |
Akebia |
A 36-Week, Single-Group, Open-Label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children with Hyperphosphatemia Related to Chronic Kidney Disease. |
Akebia |
A 24-Week, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children with Iron Deficiency Anemia Associated with Non-Dialysis Dependent Chronic Kidney Disease. |
Astra Zeneca |
A Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Doses of Sodium Zirconium Cyclosilicate (SZC) for Correction of Hyperkalaemia and Effectiveness of Same Dose to Maintain Normokalaemia. |
Relypsa |
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD) |
Roche |
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis. |
Rockwell |
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC) |